RFX6 Regulates Insulin Secretion by Modulating Ca2+ Homeostasis in Human β Cells

Vikash Chandra(Inserm), Olivier Albagli(Université Paris Cité), Benoît Hastoy(Churchill Hospital), Julie Piccand(Institut de génétique et de biologie moléculaire et cellulaire), Clotilde Randriamampita(Institut Cochin), Emmanuel Vaillant(European Genomic Institute for Diabetes), Hélène Cavé(Hôpital Robert-Debré), Kanetee Busiah(Inserm), Philippe Froguel(Institut Pasteur), Martine Vaxillaire(Centre National de la Recherche Scientifique), Patrik Rorsman(Churchill Hospital), Michel Polak(Université Paris Cité), Raphaël Scharfmann(Institut Cochin)
Cell Reports
December 1, 2014
Cited by 98Open Access
Full Text

Abstract

Development and function of pancreatic β cells involve the regulated activity of specific transcription factors. RFX6 is a transcription factor essential for mouse β cell differentiation that is mutated in monogenic forms of neonatal diabetes. However, the expression and functional roles of RFX6 in human β cells, especially in pathophysiological conditions, are poorly explored. We demonstrate the presence of RFX6 in adult human pancreatic endocrine cells. Using the recently developed human β cell line EndoC-βH2, we show that RFX6 regulates insulin gene transcription, insulin content, and secretion. Knockdown of RFX6 causes downregulation of Ca(2+)-channel genes resulting in the reduction in L-type Ca(2+)-channel activity that leads to suppression of depolarization-evoked insulin exocytosis. We also describe a previously unreported homozygous missense RFX6 mutation (p.V506G) that is associated with neonatal diabetes, which lacks the capacity to activate the insulin promoter and to increase Ca(2+)-channel expression. Our data therefore provide insights for understanding certain forms of neonatal diabetes.


Related Papers

No related papers found

Powered by citation graph analysis